Cargando…

SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery

BACKGROUND: Meningiomas are the most frequently occurring primary intracranial tumours in adults. Surgical removal can only be curative by complete resection; however surgical access can be challenging due to anatomical localization and local invasion of bone and soft tissues. Several intraoperative...

Descripción completa

Detalles Bibliográficos
Autores principales: Dijkstra, B. M., Motekallemi, A., den Dunnen, W. F. A., Jeltema, J. R., van Dam, G. M., Kruyt, F. A. E., Groen, R. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060877/
https://www.ncbi.nlm.nih.gov/pubmed/29858948
http://dx.doi.org/10.1007/s00701-018-3575-z
_version_ 1783342099312148480
author Dijkstra, B. M.
Motekallemi, A.
den Dunnen, W. F. A.
Jeltema, J. R.
van Dam, G. M.
Kruyt, F. A. E.
Groen, R. J. M.
author_facet Dijkstra, B. M.
Motekallemi, A.
den Dunnen, W. F. A.
Jeltema, J. R.
van Dam, G. M.
Kruyt, F. A. E.
Groen, R. J. M.
author_sort Dijkstra, B. M.
collection PubMed
description BACKGROUND: Meningiomas are the most frequently occurring primary intracranial tumours in adults. Surgical removal can only be curative by complete resection; however surgical access can be challenging due to anatomical localization and local invasion of bone and soft tissues. Several intraoperative techniques have been tried to improve surgical resection, including intraoperative fluorescence guided imaging; however, no meningioma-specific (fluorescent) targeting has been developed yet. Here, we aimed to identify the most promising biomarkers for targeted intra-operative fluorescence guided meningioma surgery. METHODS: One hundred forty-eight meningioma specimens representing all meningioma grades were analysed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet-derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on TArget Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumour material. RESULTS: TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 51.4% strong/diffuse, 30.4% moderate/diffuse and only 18.2% focal/weak staining patterns. All tested biomarkers showed at least weak positivity in all meningiomas, regardless of WHO grade. TASC analysis showed that SSTR-2 was the most promising target for fluorescence guided imaging, with a total score of 21 (out of 22). SSTR-2 expression was determined on original patient tumours and 3D cultures of three established cultures. CONCLUSIONS: SSTR-2 expression was highly sensitive and specific in all 148 meningiomas, regardless of WHO grade. According to TASC analysis, SSTR-2 is the most promising receptor for meningioma targeting. After establishing in vitro meningioma models, SSTR-2 cell membrane expression was confirmed in two of three meningioma cultures as well. This indicates that specific fluorescence in an experimental setting can be performed for the further development of targeted fluorescence guided meningioma surgery and near-infrared fluorescent tracers targeting SSTR-2.
format Online
Article
Text
id pubmed-6060877
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-60608772018-08-09 SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery Dijkstra, B. M. Motekallemi, A. den Dunnen, W. F. A. Jeltema, J. R. van Dam, G. M. Kruyt, F. A. E. Groen, R. J. M. Acta Neurochir (Wien) Original Article - Tumor - Meningioma BACKGROUND: Meningiomas are the most frequently occurring primary intracranial tumours in adults. Surgical removal can only be curative by complete resection; however surgical access can be challenging due to anatomical localization and local invasion of bone and soft tissues. Several intraoperative techniques have been tried to improve surgical resection, including intraoperative fluorescence guided imaging; however, no meningioma-specific (fluorescent) targeting has been developed yet. Here, we aimed to identify the most promising biomarkers for targeted intra-operative fluorescence guided meningioma surgery. METHODS: One hundred forty-eight meningioma specimens representing all meningioma grades were analysed using immunohistochemistry (IHC) on tissue microarrays (TMAs) to determine expression patterns of meningioma biomarkers epithelial membrane antigen (EMA), platelet-derived growth factor β (PDGF-β), vascular endothelial growth factor α (VEGF-α), and somatostatin receptor type 2 (SSTR-2). Subsequently, the most promising biomarker was selected based on TArget Selection Criteria (TASC). Marker expression was examined by IHC in 3D cell culture models generated from freshly resected tumour material. RESULTS: TMA-IHC showed strongest staining for SSTR-2. All cases were positive, with 51.4% strong/diffuse, 30.4% moderate/diffuse and only 18.2% focal/weak staining patterns. All tested biomarkers showed at least weak positivity in all meningiomas, regardless of WHO grade. TASC analysis showed that SSTR-2 was the most promising target for fluorescence guided imaging, with a total score of 21 (out of 22). SSTR-2 expression was determined on original patient tumours and 3D cultures of three established cultures. CONCLUSIONS: SSTR-2 expression was highly sensitive and specific in all 148 meningiomas, regardless of WHO grade. According to TASC analysis, SSTR-2 is the most promising receptor for meningioma targeting. After establishing in vitro meningioma models, SSTR-2 cell membrane expression was confirmed in two of three meningioma cultures as well. This indicates that specific fluorescence in an experimental setting can be performed for the further development of targeted fluorescence guided meningioma surgery and near-infrared fluorescent tracers targeting SSTR-2. Springer Vienna 2018-06-01 2018 /pmc/articles/PMC6060877/ /pubmed/29858948 http://dx.doi.org/10.1007/s00701-018-3575-z Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article - Tumor - Meningioma
Dijkstra, B. M.
Motekallemi, A.
den Dunnen, W. F. A.
Jeltema, J. R.
van Dam, G. M.
Kruyt, F. A. E.
Groen, R. J. M.
SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
title SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
title_full SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
title_fullStr SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
title_full_unstemmed SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
title_short SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
title_sort sstr-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery
topic Original Article - Tumor - Meningioma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060877/
https://www.ncbi.nlm.nih.gov/pubmed/29858948
http://dx.doi.org/10.1007/s00701-018-3575-z
work_keys_str_mv AT dijkstrabm sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery
AT motekallemia sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery
AT dendunnenwfa sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery
AT jeltemajr sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery
AT vandamgm sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery
AT kruytfae sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery
AT groenrjm sstr2asapotentialtumourspecificmarkerforfluorescenceguidedmeningiomasurgery